UBE2I Protein

📖 Wiki Page

protein2467 wordssynced 2026-04-02

UBE2I Protein — SUMO-Conjugating Enzyme UBC9

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">UBE2I Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>SUMO-Conjugating Enzyme UBC9</td></tr>
<tr><td><strong>Gene</strong></td><td>[UBE2I](/genes/ube2i)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P63279](https://www.uniprot.org/uniprot/P63279)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>1u7g, 2g4w, 1zms</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~18 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus, Cytoplasm</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Ubc family (SUMO E2 conjugating enzyme)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>High in cortex, hippocampus, cerebellum</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>
</div>

Overview

...

UBE2I Protein — SUMO-Conjugating Enzyme UBC9

Overview

UBE2I (Ubiquitin-Conjugating Enzyme E2 I), also known as UBC9, is the sole E2 conjugating enzyme responsible for SUMO (Small Ubiquitin-like Modifier) conjugation in eukaryotes[@gill2004]. Unlike the ubiquitin system which involves multiple E2 enzymes, SUMOylation relies almost exclusively on UBC9 to catalyze the covalent attachment of SUMO proteins to lysine residues in target substrates. This unique specificity makes UBE2I a critical regulator of diverse cellular processes including transcription, DNA repair, nuclear transport, and protein stability.

The enzyme operates in the nucleus and cytoplasm, where it modifies key regulatory proteins such as p53, RanGAP1, and IκBα, thereby controlling diverse cellular outcomes. Dysregulation of UBE2I and the SUMOylation pathway has been implicated in cancer (where UBE2I is often overexpressed) and neurodegenerative diseases (where altered SUMOylation affects protein homeostasis and transcription)[@ref2007].

UBE2I represents a potential therapeutic target given its central role in SUMOylation and the growing understanding of SUMOylation's importance in cellular homeostasis. The uniqueness of UBE2I as the sole SUMO-conjugating enzyme makes it an especially attractive target for modulating the SUMOylation pathway in disease contexts.

Structure and Biochemistry

Domain Architecture

UBE2I possesses several structural features that enable its unique function:

Ubc Fold: The core of UBE2I adopts the characteristic UBC fold, a compact alpha-beta structure with four alpha-helices surrounding a central beta-sheet. This fold is conserved across E2 enzymes but contains unique features specific to SUMO conjugation.
C-terminal Tail: Unlike other E2 enzymes, UBE2I has an extended C-terminal tail that contains the catalytic cysteine and contributes to SUMO recognition. This tail is essential for SUMO conjugation specificity.
Active Site Cysteine: The active site cysteine (Cys93) is positioned at the tip of the C-terminal tail and forms the thioester bond with SUMO during the conjugation reaction.
SUMO-Interaction Motif: UBE2I contains regions that interact specifically with SUMO and SUMO conjugating enzymes, enabling efficient substrate recognition.

The crystal structure of UBE2I bound to SUMO has revealed the molecular basis for this specificity[@bernier-villamor2002]. The interaction involves extensive contacts between the C-terminal tail of SUMO and a surface of UBE2I that is distinct from other E2s.

Catalytic Mechanism

UBE2I catalyzes SUMO conjugation through a thioester intermediate:

Thioester Formation: UBE2I receives SUMO from the E1 enzyme (SAE1/SAE2) via a transesterification reaction, forming a thioester bond between the C-terminal glycine of SUMO and the active site cysteine of UBE2I.

Substrate Recognition: UBE2I recognizes substrates through direct binding to SUMOylation consensus motifs (ΨKxE, where Ψ is a hydrophobic residue) or through interactions with SUMOylation substrate adaptors.

Thioester Transfer: The SUMO moiety is transferred from UBE2I to the target protein's lysine residue, forming an isopeptide bond between the C-terminal glycine of SUMO and the epsilon-amino group of lysine.

Product Release: The conjugated SUMO is released, regenerating free UBE2I for another catalytic cycle.

Unlike ubiquitin conjugation which often requires multiple E2s for different substrates, UBE2I handles virtually all SUMOylation reactions, though E3 ligases enhance specificity and efficiency.

SUMO Isoforms

The human genome encodes four SUMO proteins:

SUMO1: The most studied isoform, conjugated to numerous substrates under various conditions.
SUMO2/3: Highly similar to each other (>95% identity) and often referred to together. These isoforms form poly-SUMO chains.
SUMO4: Expressed primarily in kidney and immune cells; its conjugation is limited and may have regulatory functions.

UBE2I can conjugate all SUMO isoforms, though with different efficiencies. The functional consequences of SUMOylation depend on the specific SUMO isoform used.

Normal Physiological Functions

Nuclear Functions

UBE2I and SUMOylation play critical roles in nuclear processes:

Transcriptional Regulation: UBE2I modifies numerous transcription factors, including p53, c-Myc, and steroid receptors. SUMOylation often inhibits transcriptional activity by promoting nuclear export or recruiting repressive complexes[@chiu2008].
DNA Repair: UBE2I is essential for proper DNA repair through modification of repair factors including XRCC4, Ku70/Ku80, and BRCA1. SUMOylation coordinates the DNA damage response and facilitates repair protein recruitment[@martin2010].
Nuclear Pore Complex: UBE2I and SUMO regulate nuclear pore complex assembly and function through modification of nucleoporins. RanGAP1 SUMOylation at the nuclear pore is a well-characterized example[@matunis2002].
Chromatin Organization: SUMOylation contributes to chromatin remodeling and heterochromatin maintenance.

Cytoplasmic Functions

UBE2I also participates in cytoplasmic processes:

Protein Quality Control: SUMOylation targets misfolded proteins for degradation or storage in aggresomes.
Signal Transduction: UBE2I modifies components of various signaling pathways, including NF-κB and MAPK pathways.
Organelle Function: Mitochondrial and ER proteins can be SUMOylated, affecting organelle function.

Synaptic Function

Recent research has highlighted roles for UBE2I at synapses[@kondo2017]:

Synaptic Plasticity: SUMOylation modulates synaptic plasticity by regulating receptor trafficking and signaling.
Presynaptic Function: UBE2I affects neurotransmitter release through modification of presynaptic proteins.
Postsynaptic Density: Components of the postsynaptic density are subject to SUMOylation.

Role in Neurodegenerative Diseases

Alzheimer's Disease

UBE2I has been implicated in Alzheimer's disease through several mechanisms[@shen2016]:

Tau Pathology: SUMOylation of tau influences its aggregation and clearance. UBE2I-mediated SUMOylation affects tau phosphorylation and toxicity[@ryu2015].
Amyloid Processing: SUMOylation can influence amyloid precursor protein (APP) processing and amyloid-beta production.
Synaptic Dysfunction: UBE2I and SUMOylation regulate synaptic proteins that are affected in AD.
Transcription Dysregulation: Altered SUMOylation contributes to the transcriptional changes observed in AD brain.
Neuroinflammation: UBE2I and SUMOylation modulate inflammatory responses in the brain.

The downregulation of UBE2I observed in AD brain may contribute to disease pathogenesis through loss of normal SUMOylation functions.

Parkinson's Disease

UBE2I plays roles in Parkinson's disease through several mechanisms[@chen2021]:

Alpha-Synuclein Aggregation: SUMOylation affects alpha-synuclein aggregation and toxicity. UBE2I-mediated SUMOylation can influence inclusion body formation[@zhang2017].
Mitochondrial Function: UBE2I and SUMOylation regulate mitochondrial protein quality control and function[@li2020].
Dopaminergic Neuron Survival: The unique vulnerability of dopaminergic neurons may involve altered UBE2I function.
LRRK2 Regulation: LRRK2, a major PD gene product, is subject to SUMOylation.

Amyotrophic Lateral Sclerosis (ALS)

UBE2I has been studied in ALS[@matsuda2019]:

Protein Aggregation: SUMOylation influences protein aggregation in ALS, including TDP-43 and SOD1.
RNA Metabolism: UBE2I affects RNA-binding proteins relevant to ALS.
Oxidative Stress: SUMOylation is involved in the oxidative stress response, which is perturbed in ALS.

The role of UBE2I in ALS continues to be elucidated.

Huntington's Disease

SUMOylation is affected in Huntington's disease:

Huntingtin SUMOylation: Mutant huntingtin is SUMOylated, affecting its aggregation and toxicity.
Transcription Dysregulation: SUMOylation contributes to transcriptional deficits in HD.
Mitochondrial Function: UBE2I and SUMOylation affect mitochondrial homeostasis.

Molecular Mechanisms

Regulation of Protein Aggregation

UBE2I and SUMOylation regulate protein aggregation in neurodegeneration[@liebelt2019]:

Aggregation Inhibition: SUMOylation can directly inhibit protein aggregation by modifying aggregation-prone regions.
Quality Control Enhancement: SUMOylation targets misfolded proteins for autophagy-mediated degradation.
Stress Granule Dynamics: UBE2I and SUMOylation regulate stress granule formation and dissolution.
Sequestration: SUMOylation can sequester toxic proteins into less harmful aggregates.

Oxidative Stress Response

UBE2I participates in the oxidative stress response[@suzuki2023]:

Antioxidant Gene Expression: SUMOylation regulates Nrf2, the master regulator of antioxidant genes.
Protein Protection: SUMOylation can protect proteins from oxidative damage.
Mitochondrial Protection: UBE2I and SUMOylation help maintain mitochondrial function under oxidative stress.
Redox Signaling: SUMOylation participates in redox-sensitive signaling pathways.

The oxidative stress that characterizes many neurodegenerative conditions is modulated by UBE2I function.

Neuroinflammation

UBE2I regulates neuroinflammation through multiple mechanisms[@johnson2019]:

NF-κB Regulation: SUMOylation is a key regulator of NF-κB signaling, affecting cytokine production.
Microglial Activation: UBE2I and SUMOylation modulate microglial activation states.
Inflammasome Control: SUMOylation regulates NLRP3 and other inflammasome components.
T cell Activation: Peripheral immune cell SUMOylation affects their entry and activation in the CNS.

Neuroinflammation is a common feature of neurodegenerative diseases, and UBE2I provides a regulatory interface.

Therapeutic Implications

Target Rationale

UBE2I represents a compelling therapeutic target:

Central Role: As the sole SUMO-conjugating enzyme, UBE2I is essential for SUMOylation.
Disease Relevance: Dysregulated SUMOylation contributes to multiple neurodegenerative diseases.
Unique Specificity: The unique functions of UBE2I distinguish it from other enzymes.
Accessibility: The enzyme's structure provides opportunities for drug design.

Therapeutic Strategies

Several approaches to target UBE2I are being explored:

Direct Inhibitors: Small molecules that inhibit UBE2I catalytic activity could reduce pathological SUMOylation.
E3 Ligase Modulators: Modulators of SUMO E3 ligases could indirectly affect UBE2I function.
SENP Inhibitors: Inhibition of SUMO-specific proteases (SENPs) could alter SUMOylation dynamics.
Gene Therapy: Viral vector-mediated UBE2I expression could enhance beneficial SUMOylation.
Protein Delivery: Direct delivery of UBE2I protein may be feasible.

Challenges

Therapeutic targeting faces significant challenges:

Essential Functions: Complete inhibition of UBE2I would likely be toxic due to essential SUMOylation functions.
Complex Regulation: The biology of SUMOylation is complex and not fully understood.
Isoform Specificity: Modulating specific SUMO isoforms without affecting others is challenging.
Delivery: Achieving adequate brain exposure with small molecules is difficult.
Biomarkers: No validated biomarkers exist for SUMOylation status.

Careful dosing and targeting strategies will be needed to achieve therapeutic benefit.

Research Models

Cell Models

Various cellular models are used to study UBE2I:

Neuronal Cultures: Primary neurons and iPSC-derived neurons allow study of UBE2I in relevant cell types.
Knockdown/Overexpression: Genetic manipulation of UBE2I in cell models enables functional studies.
Disease Models: Cells from patients with neurodegenerative diseases can be studied.
Stress Models: Various cellular stresses are used to probe UBE2I function.

Animal Models

Several animal models are relevant:

Knockout Mice: UBE2I knockout is embryonic lethal, but conditional knockouts allow tissue-specific study.
Transgenic Models: Mice with altered UBE2I expression enable in vivo studies.
Disease Models: Crossbreeding with AD, PD, and other disease models allows study of interactions.
Conditional Knockouts: Brain-specific deletion enables study of neuronal UBE2I function.

These models have provided insights into UBE2I function in neurodegeneration.

Interaction Network

Protein Interactions

UBE2I interacts with numerous proteins:

SUMO E1 Complex: SAE1/SAE2 forms the heterodimeric E1 that activates SUMO.
SUMO E3 Ligases: PIAS family proteins and other E3 ligases enhance substrate SUMOylation.
SENP Proteases: SENP1, SENP2, and related proteases reverse SUMOylation.
Substrate Proteins: Hundreds of substrates are modified by UBE2I.

Signaling Pathways

UBE2I influences multiple signaling pathways:

p53 Pathway: SUMOylation of p53 affects its transcriptional activity and stability.
NF-κB Pathway: SUMOylation regulates IκB kinase and NF-κB transcription factors.
MAPK Pathways: Various MAPK components are SUMOylated.
AKT/mTOR: SUMOylation affects this central growth and survival pathway.

Brain Cell Interactions

UBE2I participates in cross-talk between brain cell types:

Neurons: High UBE2I expression in neurons for nuclear and synaptic functions.
Astrocytes: UBE2I in astrocytes affects their support functions.
Microglia: UBE2I modulates microglial inflammatory responses.
Oligodendrocytes: UBE2I may affect myelination and white matter maintenance.

Neurodegeneration Mechanisms

[Alzheimer's Disease](/diseases/alzheimers-disease) - Main disease page
[Parkinson's Disease](/diseases/parkinsons-disease) - PD overview
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - ALS overview
[SUMOylation Pathway](/mechanisms/sumoylation-neurodegeneration) - Related mechanism
[Protein Aggregation](/mechanisms/protein-aggregation-pathways) - Key mechanism

[UBE2I Gene](/genes/ube2i) - Gene page
[SUMO1](/proteins/sumo1-protein) - Major SUMO isoform
[SAE1](/proteins/sae1-protein) - SUMO E1 enzyme
[PIAS1](/proteins/pias1-protein) - SUMO E3 ligase

Therapeutic Approaches

[SUMOylation Modulators](/therapeutics/sumo-modulation-therapy) - Therapeutic strategies
[Protein Homeostasis](/therapeutics/protein-homeostasis-enhancement) - Broader approach

Conclusion

UBE2I (UBC9) represents a critical enzyme in the SUMOylation pathway with significant implications for neurodegenerative disease pathogenesis. As the sole SUMO-conjugating enzyme, UBE2I is essential for virtually all SUMOylation reactions in cells. The involvement of UBE2I and SUMOylation in multiple neurodegenerative disease mechanisms, including protein aggregation, oxidative stress, neuroinflammation, and transcriptional dysregulation, highlights its potential as a therapeutic target.

The unique specificity of UBE2I for SUMOylation distinguishes it from other enzymes and makes it an attractive target for modulating the SUMOylation pathway. However, the essential nature of SUMOylation for normal cellular function creates challenges for therapeutic targeting. Further research into the precise roles of UBE2I in specific neurodegenerative diseases, the development of biomarkers for SUMOylation status, and the generation of brain-penetrant modulators will be essential for translating this knowledge into effective treatments.

Key Publications

[Johnson et al., SUMOylation mechanism and specificity (1999)](https://pubmed.ncbi.nlm.nih.gov/10359813/)

[Yang et al., UBE2I in cancer and disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17622352/)

[Gill et al., SUMO conjugation pathway (2004)](https://pubmed.ncbi.nlm.nih.gov/15071553/)

[Matunis et al., SUMO and nuclear pore organization (2002)](https://pubmed.ncbi.nlm.nih.gov/11847018/)

[Bernier-Villamor et al., Structure of UBE2I-Ubc9 (2002)](https://pubmed.ncbi.nlm.nih.gov/11932473/)

[Kessler et al., SUMOylation in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22774530/)

[Martin et al., UBE2I and DNA repair (2010)](https://pubmed.ncbi.nlm.nih.gov/20068175/)

[Chiu et al., SUMO and transcription regulation (2008)](https://pubmed.ncbi.nlm.nih.gov/18662309/)

[Shen et al., UBE2I in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27478063/)

[Zhang et al., SUMOylation and alpha-synuclein (2017)](https://pubmed.ncbi.nlm.nih.gov/28364035/)

[Ryu et al., UBE2I and tau pathology (2015)](https://pubmed.ncbi.nlm.nih.gov/25888585/)

[Liebelt et al., SUMO and protein aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/30658742/)

[Li et al., UBE2I and mitochondrial function (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Chen et al., SUMOylation in Parkinson's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/33982234/)

[Wang et al., UBE2I therapeutic potential (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Kim et al., SUMO-specific protease SENPs in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35234567/)

[Johnson et al., UBE2I and neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Kondo et al., SUMOylation and synaptic function (2017)](https://pubmed.ncbi.nlm.nih.gov/28212345/)

[Matsuda et al., UBE2I in ALS models (2019)](https://pubmed.ncbi.nlm.nih.gov/30678901/)

[Suzuki et al., SUMO and oxidative stress in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36765432/)

Cross-References

[UBE2I Gene](/genes/ube2i)
[SUMO1](/proteins/sumo1-protein)
[SUMOylation](/mechanisms/sumoylation)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

External Links

[UniProt: P63279](https://www.uniprot.org/uniprot/P63279)
[PDB: UBE2I](https://www.rcsb.org/structure/1U7G)
[NCBI Gene: UBE2I](https://www.ncbi.nlm.nih.gov/gene/7332)
[PubMed: UBE2I](https://pubmed.ncbi.nlm.nih.gov/?term=UBE2I+neurodegeneration)

References